Prescription of personalized therapies in non-small cell lung carcinoma is mainly based on histological subtype and molecular abnormalities in tumor specimens.
Together, these developments show that treatment for NSCLC is evolving toward a more personalized approach based on histological subtype or the molecular or genetic profile of the tumor.
Despite this, no patient stratification or population enrichment based on histological subtype, IGF-1R tumour expression or circulating fIGF1 levels was pursued in Phase III trials (Jassem et al, 2010).
Considering the morphological, anatomical and clinical differences between tumours, three main classification parameters have emerged, which are based on histological subtype (serous, endometrioid, clear cells, mucinous, Brenner), disease stage (I IV) and tumour grade (0 3).
Third, the introduction of pemetrexed has revealed differences in OS based on histological subtype of NSCLC, with the efficacy of pemetrexed being superior to that of gemcitabine in combination with cisplatin in individuals with non-squamous NSCLC (especially adenocarcinoma), and the opposite being true for those with squamous cell carcinoma.
Classification of BC is currently based on histological types and molecular subtypes in order to reflect the hormone-responsiveness of the tumour.
The features were created based on histological basis (two histologic grades times three histological types).
Based on histological criteria, it can be classified into two major subtypes, alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS).
Based on histological findings and cytological aberrations, liposarcomas are classified into four subtypes: well differentiated, myxoid, pleomorphic, and round cell.
However for RI MTBE studies, incidences of lymphoma subtypes (e.g., lymphoblastic and immunoblastic lymphomas) were reported based on histological examination via light microscopy (Belpoggi et al. 1999).
